← Eichor
Study identifier: NCT03296826 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Condition: BRCA1 and/or BRCA2 Variant Carriers · Ovarian Carcinoma · Fallopian Tube Carcinoma  ·  Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

PhaseN/A
Planned participants600
Who can joinFemale, 20 Years to no upper limit
Healthy volunteersNo

About this study

To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.

This description comes directly from the study's public registry record.

Talk to the study team

Akira Hirasawa, M.D., Ph.D.  ·  +81-86-235-7436  ·  hir-aki45@umin.org

Always discuss trial participation with your own doctor first.

Locations (1)

Okayama UniversityOkayama, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03296826